TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02449278
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in both arms will be given cyclophosphamide chemotherapy
Study: NCT02449278
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in both arms will be given doxorubicin chemotherapy
Study: NCT02575833
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of a matching volume of placebo infused over approximately 60 minutes.
Study: NCT00002897
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03290963
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, dosed in units
Study: NCT01835041
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01835041
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02254265
Drug: OTX-101 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTX-101 0.05% Ophthalmic Solution
Study: NCT02254265
Drug: OTX-101 0.09%
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTX-101 0.09% Ophthalmic Solution
Study: NCT02254265
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle of OTX-101 Ophthalmic Solution
Study: NCT04530643
Drug: HY209 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 subjects will be assigned to drug (HY209 0.3% gel).
Study: NCT04530643
Drug: HY209 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 subjects will be assigned to drug (HY209 0.5% gel).
Study: NCT04530643
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 subjects will be assigned to drug (Placebo).
Study: NCT01547390
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03015246
Drug: Placebo stressor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose
Study: NCT00865761
Drug: XANAX XR® 3 mg tablets, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Pharmacia \& Upjohn Company formulated products under fasting conditions
Study: NCT02101125
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01849965
Drug: DSC127
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever occurs sooner.
Study: NCT01849965
Drug: placebo vehicle gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01849965
Drug: Standard of Care gel, Aquasite
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00287586
Drug: Testosterone Gel (Androgel)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years
Study: NCT02102113
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02640482
Drug: ABT-493/ABT-530
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; ABT-493 coformulated with ABT-530
Study: NCT02640482
Drug: Placebo for ABT-493/ABT-530
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT03612921
Drug: placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet
Study: NCT02670616
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 IV day 1
Study: NCT02670616
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 IV day 1
Study: NCT02670616
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg per day on day 1-5
Study: NCT00290550
Drug: MK0457
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion at 10 mg/m2/hour; 5-day continuous infusion every 21 days
Study: NCT03162874
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID
Study: NCT03162874
Drug: PXT002331 - dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT03280264
Drug: KHK7580
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT01153425
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants are clinically indicated for treatment.
Study: NCT02262455
Drug: Liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal doxorubicin (40 mg/m2) will be administered once every 28 days by IV infusion prior to STM 434 for those participants enrolled in Part 3 of the trial. Liposomal doxorubicin will be administered for a maximum of 6 cycles (each cycle being 28 days).
Study: NCT04402411
Drug: Intravenous opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive morphine 0.1 mg/kg
Study: NCT03027960
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg placebo for a 2-week period
Study: NCT00985244
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin during 1 year.
Study: NCT02543944
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline cellulose
Study: NCT00172029
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04080739
Drug: ropivicaine 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-8 cc/hr of 0.2% ropivicaine given as a regional block via US-guided ipsilateral sciatic nerve block for fibula free flap patients or US-guided infraclavicular brachial plexus nerve block for forearm free flap patients.
Study: NCT03154125
Drug: Sayana® Press
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active ingredient in Sayana® Press is Medroxyprogesterone acetate (MPA). Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) for subcutaneous injection.
Study: NCT01867918
Drug: Standard Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02413229
Drug: DSXS1411
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSXS (Taro Pharmaceuticals Inc.)
Study: NCT02413229
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle) (Taro Pharmaceuticals Inc.)
Study: NCT02955212
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral administration
Study: NCT04069819
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01087359
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg melatonin is tested on human endotoxaemia administrated on night and day time compared to placebo
Study: NCT00738387
Drug: ASA404
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1800 mg/m2 of ASA404 i.v. on day 1 of each 21 day cycle
Study: NCT01057511
Drug: Crinone 8%
Normalized name: Crinone 8% Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crinone 8%, 90mg / p.v. / Qd, 7 days totally.
Study: NCT02070965
Drug: Comp01 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02744872
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00054457
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02515331
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule - oral dose
Study: NCT02902523
Drug: Viread® tablet 300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administration(PO) in the fasted state
Study: NCT02902523
Drug: HUG116 tablet 245mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administration(PO) in the fasted state
Study: NCT00567008
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo BID for 8 weeks
Study: NCT03305848
Drug: Nitrostat 0.4Mg Sublingual Tablet
Normalized name: Nitrostat 0.4mg Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 3 administrations of 0.4mg sublingual nitroglycerin tablets, dissolved in 10mL tap water, given orally in a single swallow. Each administration is separated by at least 5 minutes, and only if systolic blood pressure \> 100 mmHg.
Study: NCT02939794
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (normal saline, sodium chloride)
Study: NCT03452943
Drug: TEV-50717
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6, 9, 12, 15, and 18 mg oral tablets
Study: NCT03452943
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to TEV-50717 tablets will be taken BID for 12 weeks.
Study: NCT03910985
Drug: Duovent HFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: bronchodilation
Study: NCT00302289
Drug: tyrosine, green tea, caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02688738
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02252354
Drug: [14C]-TAK-385 Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-385 oral radiolabelled solution
Study: NCT02252354
Drug: [14C]-TAK-385 Solution for Intravenous Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-385 intravenous (IV) radiolabelled solution
Study: NCT04470063
Drug: DDO-3055 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-dose for DDO-3055 tablets
Study: NCT04470063
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-dose for Placebo
Study: NCT04594681
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered once daily or three times daily.
Study: NCT04594681
Drug: KHK4951
Approvals — FDA: no, EMA: no, PMDA: no
Description: KHK4951 is administered once daily or three times daily.
Study: NCT03709043
Drug: Standardized kudzu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized kudzu
Study: NCT01330303
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: SECOTEX® (tamsulosin hydrochloride) 0,4 mg (Boehringer Ingelheim)
Study: NCT01330303
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: tamsulosin hydrochloride 0,4 mg (Synthon BV)
Study: NCT00857571
Drug: 150 mg Tablet
Normalized name: Ogsiveo 150 MG Tablet 7-Day 14 Count Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 150 mg of PF-02413873 tablets
Study: NCT00857571
Drug: 30 mg Tablet
Normalized name: Triumeq PD 60 MG / 5 MG / 30 MG Tablet for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 30 mg of PF-02413873 tablets
Study: NCT00857571
Drug: 400 mg Tablet
Normalized name: Aciclovir 400 mg tablet for oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 400 mg of PF-02413873 tablets
Study: NCT00857571
Drug: 5 mg Tablet
Normalized name: Meloxicam 7.5 mg TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 5 mg of PF-02413873 tablets
Study: NCT00857571
Drug: 750 mg Tablet
Normalized name: Spritam 750 MG Tablet for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 750 mg of PF-02413873 tablets
Study: NCT00613171
Drug: STI571
Approvals — FDA: no, EMA: no, PMDA: no
Description: STI571 tablets taken orally once a day
Study: NCT00564512
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)
Study: NCT01026246
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo used will be normal saline (0.9 percent NaCl).
Study: NCT00481117
Drug: LY2405319
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00481117
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02907060
Drug: Pharmacological cervical ripening
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: The comparative pharmacological procedure is a vaginal slow releasing system of dinoprostone. The form used in the study is Propess (Ferring pharmaceuticals) containing 10mg of dinoprostone (prostaglandin E2).~It will be used in accordance with Summary of Product Characteristics
Study: NCT04563936
Drug: LY01005 3.6 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY01005 was administered as 3 intramuscular (IM) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
Study: NCT04563936
Drug: ZOLADEX® 3.6 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZOLADEX® was administered as 3 Subcutaneous (SC) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
Study: NCT00138008
Drug: endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: endocrine therapy
Study: NCT00491868
Drug: R744 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 μg/4week for 24 weeks
Study: NCT00491868
Drug: rHuEPO placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 IU 2 or 3 times/week for 8 weeks, then 1\~3 times/week for 16 weeks
Study: NCT04991207
Drug: BIA 5-1058
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral BIA 5-1058 (Zamicastat) 100 mg tablets
Study: NCT03399071
Drug: FLOT-A
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a single-arm study with all patients receiving combination FLOT-A
Study: NCT00150280
Drug: celecoxib and ibuprofen SR
Normalized name: amlodipine and celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04359147
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Effects on neural correlates of decision-making under risk and selective attention to threat
Study: NCT04359147
Drug: Yohimbine + Hydrocortisone
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effects on neural correlates of decision-making under risk and selective attention to threat
Study: NCT04359147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effects on neural correlates of decision-making under risk and selective attention to threat
Study: NCT03355612
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capecitabine:1000 mg/m2 bid d1-14 q3w, Oxaliplatin:130 mg/m2 d1 q3w
Study: NCT01112059
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg twice a day for 8 days
Study: NCT00091611
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01922505
Drug: PPI triple therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03759392
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo twice daily for up to 20 weeks
Study: NCT03573622
Drug: Anpl-one SR Tab. 300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets
Study: NCT03573622
Drug: Sarpodipil SR Tab. 300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
Study: NCT02456740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection once a month
Study: NCT01243957
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine: 60 mg po QD for 7 days (Days 4-10) then 20 mg po QD for 17 days (Days 11-27)
Study: NCT03817190
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT03689465
Drug: CTX
Normalized name: CTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: In PTCy-ATG group, CTX will be intravenously infused via a central venous catheter on day +4 at a dose of 50mg/kg/d.
Study: NCT04208152
Drug: anle138b
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule containing excipient and anle138b
Study: NCT01937871
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00970593
Drug: placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 \& 2: PBO x 7 days BID Group 3: PBO QD x 14 days Group 4: PBO QD x 14 days Group 5: PBO QD x 14 days Group 6: PBO QD x 14 days
Study: NCT03719625
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparaison of Norepinephrin and Ephedrin for prevention of the post spinal anesthesia in cesarean section
Study: NCT04647903
Drug: ADAIR 10 mg IR tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: manipulated ADAIR 3x10mg
Study: NCT04647903
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for oral and intranasal administration
Study: NCT02807337
Drug: Caphosol
Normalized name: Caphosol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02807337
Drug: 0,9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00696215
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 mg once a day
Study: NCT04468685
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interperitoneal administration in the gall bladder bed
Study: NCT00648778
Drug: Loxitane® Capsules 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg, single dose fasting
Study: NCT01722578
Drug: L-ornithine L-aspartate
Normalized name: L-ornithine L-aspartate
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-ornithine L-aspartate (6 ampules, each ampule containing 5 grams of the drug in 10 ml solution) to be diluted in 440 ml of Dextrose 5% (to make a total of 500 ml of solution), as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
Study: NCT01722578
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sterile water, 60 ml) diluted in 440 ml of Dextrose 5%, as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
Study: NCT02531529
Drug: dexmedetomedine
Approvals — FDA: no, EMA: no, PMDA: no
Description: intraoperative infusion
Study: NCT02531529
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03252067
Drug: azithromycin eyedrop
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tear samples will be collected using the strips.
Study: NCT02288312
Drug: BIA 2-093
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02411825
Drug: SAR425899
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study: NCT02411825
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study: NCT00714116
Drug: SBI-087
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV or SC dose of SBI-087
Study: NCT01863914
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arteriovenous fistula surgery was performed after 1-week treatment with placebo or Rosuvastatin (randomized, double blind). The intervention drug treatment continues for 3 more weeks after creation of AV fistula.
Study: NCT01951924
Drug: Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03399513
Drug: R-CHOEP chemotherapy
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunochemotherapy
Study: NCT04584684
Drug: 0.12% Chlorohexidine Gluconate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentist prescribed antimicrobial mouth rinse
Study: NCT04584684
Drug: 27% Ethanol plus essential oils
Approvals — FDA: no, EMA: no, PMDA: no
Description: Over-the-counter antiseptic mouth rinse
Study: NCT02726659
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunct celecoxib
Study: NCT02726659
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunct placebo
Study: NCT04629378
Drug: Rifafour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifafour (HRZE) Standard dose
Study: NCT00545714
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 250 mg/m\^2 as IV infusion will be administered on Days 1-3 of first six 28-day cycles.
Study: NCT00995124
Drug: NeutraLice Lotion
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Head lice topical application to be applied once for 10 minutes.
Study: NCT00995124
Drug: NeutraLice Advance Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: head lice application to be applied once for 10 minutes
Study: NCT00995124
Drug: Moov Head Lice Solution
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single application for head lice with 10 min application time.
Study: NCT03997812
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of 0 mg of VVZ-149
Study: NCT03889886
Drug: SDP-4 Ophthalmic Solution (0.1%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
Study: NCT03889886
Drug: SDP-4 Ophthalmic Solution (1.0%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
Study: NCT03889886
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.